A Phase 2 interventional study of OC-01 (varenicline) nasal spray and Placebo (vehicle control) nasal spray in Dry Eye Disease, sponsored by Oyster Point Pharma, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-29.
Sponsored by Oyster Point Pharma, Inc. (part of Viatris Inc.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing varenicline in Dry Eye Syndromes — 2 open to participants now, 2 under way, none of them phase 3. Varenicline · Dry Eye Syndromes.
Among the 13 studies testing varenicline in Dry Eye Syndromes, this one is the 12th largest by enrollment, is one of 2 that started in 2018, is one of 3 in phase 2, and was the 2nd registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.
Browse Dry Eye Syndromes studies →2 of the 13 studies testing varenicline in Dry Eye Syndromes are open now, in 1 country. Recruiting first, the newest first:
Ocular Aesthetics, LLC dba Ocular Clinical Trials · Sites in United States
Ages 18–99 · Healthy volunteers
University of California, Berkeley · Sites in United States
Ages 18+
By country, each count listing its studies:
Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 2 started in 2018.
This study's enrollment of 18 is below the median of 60 across 1,129 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 60 across the 13 interventional studies. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 13 have an industry lead sponsor. The 9 most frequent:
This study is registered under Oyster Point Pharma, Inc., one of the names counted as Viatris Inc.. Under that name alone:
Oyster Point Pharma, Inc. is the lead sponsor of 11 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 10 (100%) have results posted.
Viatris Inc. has 9 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
2 of the studies testing varenicline in Dry Eye Syndromes that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07705893Ocular Aesthetics, LLC dba Ocular Clinical TrialsTreating Contact Lens Discomfort With Varenicline Solution Nasal Spray 0.03mg | 2026-12 |
| NCT07606625University of California, BerkeleyOcular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye Treatment | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies testing varenicline in Dry Eye Syndromes, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the safety and effectiveness of OC-01 Nasal Spray as compared to placebo in simulating Goblet Cell and Meibomian Gland function in adult subjects with DED.
This was a Phase 2, single-center, randomized, masked (including all subjects, investigators, and study site personnel), placebo-controlled study designed to evaluate the safety and efficacy of OC-01 (varenicline) nasal spray in stimulating goblet cell and Meibomian gland function in in adult subjects with DED. Approximately 45 subjects at least 18 years of age with a physicians' diagnosis of DED and meeting all other study eligibility criteria were planned to be randomized to receive a single application of 0.2% (1.2 mg/mL) OC-01 or placebo
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
OC-01 (varenicline) nasal spray, 1.2 mg/mL, one time dosing
Drug: OC-01 (varenicline) nasal spray
Placebo (vehicle control) nasal spray, one time dosing
Drug: Placebo (vehicle control) nasal spray
OC-01 (varenicline) nasal spray
Placebo
Mean Change in Goblet Cell Area
Mean change in Goblet Cell Area with a larger decrease is indicative of a better outcome.
Time frame: Baseline (pre-treatment), 1 day (post treatment)
Mean Change in Goblet Cell Perimeter
Mean change in Goblet Cell Perimeter. A larger decrease is indicative of a better outcome.
Time frame: Baseline (pre-treatment), 1 day (post treatment)
Change in Meibomian Gland Area, Upper Lid
Change in Meibomian gland area, upper lid. A larger decrease is indicative of a better outcome
Time frame: Baseline (pre-treatment), 1 day (post treatment)
Mean Change in Meibomian Gland Area, Lower Lid.
Mean change in Meibomian Gland Area, lower Lid. A larger decrease is indicative of a better outcome.
Time frame: Baseline (pre-treatment), 1 day (post treatment)
Mean Change in Meibomian Gland Perimeter, Upper Lid.
Chane in Meibomian Gland Perimeter, upper lid. A larger decrease is indicative of a better outcome.
Time frame: Baseline (pre-treatment), 1 day (post treatment)
Mean Change in Meibomian Gland Perimeter, Lower Lid
Mean change in Meibomian Gland Perimeter, lower lid. A larger decrease is indicative of a better outcome.
Time frame: Baseline (pre-treatment), 1 day (post treatment)
| Milestone | OC-01 (Varenicline) Nasal Spray, 1.2 mg/mL | Placebo (Vehicle Control) Nasal Spray |
|---|---|---|
| Started | 12 | 6 |
| Completed | 11 | 6 |
| Not completed | 1 | 0 |
Mean change in Goblet Cell Area with a larger decrease is indicative of a better outcome.
| um | OC-01, 1.2 mg/mL | Placebo |
|---|---|---|
| Mean Change in Goblet Cell Area | -38.8 ± 30.20 | -6.7 ± 1.94 |
Mean change in Goblet Cell Perimeter. A larger decrease is indicative of a better outcome.
| um | OC-01, 1.2 mg/mL | Placebo |
|---|---|---|
| Mean Change in Goblet Cell Perimeter | -7.7 ± 5.79 | -1.8 ± 0.76 |
Change in Meibomian gland area, upper lid. A larger decrease is indicative of a better outcome
| um | OC-01, 1.2 mg/mL | Placebo |
|---|---|---|
| Change in Meibomian Gland Area, Upper Lid | 11.2 ± 118.6 | -143.2 ± 154.8 |
Mean change in Meibomian Gland Area, lower Lid. A larger decrease is indicative of a better outcome.
| um | OC-01, 1.2 mg/mL | Placebo |
|---|---|---|
| Mean Change in Meibomian Gland Area, Lower Lid. | -29.9 ± 88.1 | -12.4 ± 95.8 |
Chane in Meibomian Gland Perimeter, upper lid. A larger decrease is indicative of a better outcome.
| um | OC-01, 1.2 mg/mL | Placebo |
|---|---|---|
| Mean Change in Meibomian Gland Perimeter, Upper Lid. | 6.15 ± 16.6 | -19.2 ± 22.8 |
Mean change in Meibomian Gland Perimeter, lower lid. A larger decrease is indicative of a better outcome.
| um | OC-01, 1.2 mg/mL | Placebo |
|---|---|---|
| Mean Change in Meibomian Gland Perimeter, Lower Lid | -4 ± 10.9 | 4.2 ± 19.3 |
Collected over Adverse events were collected from the time of study drug administration to the last study visit (pre to post treatment 1 day).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OC-01, 1.2 mg/mL | 0/12 (0%) | 0/12 (0%) | 6/12 (50%) |
| Placebo | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Event | OC-01, 1.2 mg/mL | Placebo |
|---|---|---|
| SneezingRespiratory, thoracic and mediastinal disorders | 5/12 | 1/6 |
| Nasal discomfortRespiratory, thoracic and mediastinal disorders | 2/12 | 0/6 |
| TEAEEye disorders | 0/12 | 0/6 |
| Age, Continuous(years) | OC-01, 1.2 mg/mL | Placebo | Total |
|---|---|---|---|
| Mean | 60.5 ± 13.79 | 63.3 ± 13.46 | 61.4 ± 13.35 |
| Sex: Female, Male(Participants) | OC-01, 1.2 mg/mL | Placebo | Total |
|---|---|---|---|
| Female | 11 | 3 | 14 |
| Male | 1 | 3 | 4 |
| Ethnicity (NIH/OMB)(Participants) | OC-01, 1.2 mg/mL | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 11 | 6 | 17 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | OC-01, 1.2 mg/mL | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 2 |
| White | 9 | 6 | 15 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | OC-01, 1.2 mg/mL | Placebo | Total |
|---|---|---|---|
| United States | 12 | 6 | 18 |
| Schirmer's Test Score(mm) | OC-01, 1.2 mg/mL | Placebo | Total |
|---|---|---|---|
| Mean | 6.6 ± 4.42 | 4.5 ± 3.89 | 5.9 ± 4.25 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2018 to primary completion in Sep 2019, 12 months.
Results were first posted in Dec 2021, 2 years 2 months after primary completion. A results delay was requested in Jan 2021.
Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's 12 months is above that.
Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Varenicline